<DOC>
	<DOCNO>NCT00114205</DOCNO>
	<brief_summary>RATIONALE : Giving drug , docetaxel , directly pleura surgery drain pleural effusion may help keep fluid building . PURPOSE : This phase I trial study side effect , best way give , best dose intrapleural docetaxel give surgery patient malignant pleural effusion .</brief_summary>
	<brief_title>Surgery Intrapleural Docetaxel Treating Patients With Malignant Pleural Effusion</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose intrapleural docetaxel patient malignant pleural effusion . Secondary - Determine toxicity profile drug patient . - Determine pharmacokinetics drug plasma pleural fluid patient . - Determine response patient treated drug . OUTLINE : This dose-escalation study . Patients undergo thorascopic surgery drain malignant pleural effusion . An intrapleural catheter ( Pleurx catheter ) insert subsequent docetaxel instillation . Approximately 24 hour surgery , patient receive docetaxel intrapleurally 3 minute via Pleurx catheter . The Pleurx catheter clamp 4 hour patient place several different position ensure uniform distribution docetaxel throughout pleural cavity . Cohorts 3-6 patient receive escalate dos intrapleural docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow week 1 3 monthly thereafter . PROJECTED ACCRUAL : Approximately 8-24 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant pleural effusion ( MPE ) Symptomatic disease Candidate thoracoscopic surgery treatment MPE No known suspect ipsilateral pleurodesis would preclude surgery No bilateral MPEs No progressive extrapleural disease untreatable and/or resistant systemic treatment PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Hepatic ALT and/or AST ≤ 1.5 time upper limit normal ( ULN ) ( alkaline phosphatase normal ) OR Alkaline phosphatase ≤ 2.5 time ULN ( ALT and/or AST normal ) Bilirubin normal INR ≤ 1.5 Renal Creatinine ≤ 1.8 mg/dL Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception ≥ 1 month completion study treatment No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No peripheral neuropathy &gt; grade 1 PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No concurrent systemic chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>malignant pleural effusion</keyword>
</DOC>